KR101840092B1 - A pharmaceutical composition for preventing or treating peripheral neurodegenerative diseases comprising ethyl pyruvate - Google Patents
A pharmaceutical composition for preventing or treating peripheral neurodegenerative diseases comprising ethyl pyruvate Download PDFInfo
- Publication number
- KR101840092B1 KR101840092B1 KR1020150147394A KR20150147394A KR101840092B1 KR 101840092 B1 KR101840092 B1 KR 101840092B1 KR 1020150147394 A KR1020150147394 A KR 1020150147394A KR 20150147394 A KR20150147394 A KR 20150147394A KR 101840092 B1 KR101840092 B1 KR 101840092B1
- Authority
- KR
- South Korea
- Prior art keywords
- nervous system
- peripheral nervous
- composition
- disease
- preventing
- Prior art date
Links
- XXRCUYVCPSWGCC-UHFFFAOYSA-N Ethyl pyruvate Chemical compound CCOC(=O)C(C)=O XXRCUYVCPSWGCC-UHFFFAOYSA-N 0.000 title claims abstract description 103
- 229940117360 ethyl pyruvate Drugs 0.000 title claims abstract description 103
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 14
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract description 49
- 230000004770 neurodegeneration Effects 0.000 title abstract description 6
- 230000002093 peripheral effect Effects 0.000 title description 3
- 210000001428 peripheral nervous system Anatomy 0.000 claims abstract description 58
- 239000000203 mixture Substances 0.000 claims abstract description 52
- 150000003839 salts Chemical class 0.000 claims abstract description 49
- 210000004116 schwann cell Anatomy 0.000 claims abstract description 42
- 235000013305 food Nutrition 0.000 claims abstract description 31
- 239000004480 active ingredient Substances 0.000 claims abstract description 19
- 238000011282 treatment Methods 0.000 claims abstract description 18
- 238000000034 method Methods 0.000 claims abstract description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
- 239000003814 drug Substances 0.000 claims description 18
- 229940079593 drug Drugs 0.000 claims description 13
- 230000018044 dehydration Effects 0.000 claims description 12
- 238000006297 dehydration reaction Methods 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 10
- 230000004663 cell proliferation Effects 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims description 6
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 2
- 208000005156 Dehydration Diseases 0.000 claims 9
- 208000035758 Charcot-Marie-Tooth disease type 2S Diseases 0.000 claims 5
- 238000011321 prophylaxis Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 abstract description 17
- 230000035755 proliferation Effects 0.000 abstract description 8
- 230000004069 differentiation Effects 0.000 abstract description 2
- 210000003497 sciatic nerve Anatomy 0.000 description 22
- 230000000694 effects Effects 0.000 description 18
- 210000005036 nerve Anatomy 0.000 description 18
- 108010009254 Lysosomal-Associated Membrane Protein 1 Proteins 0.000 description 16
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 13
- 238000001262 western blot Methods 0.000 description 13
- 230000036541 health Effects 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 9
- 238000004925 denaturation Methods 0.000 description 8
- 230000036425 denaturation Effects 0.000 description 8
- 238000012744 immunostaining Methods 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 239000003550 marker Substances 0.000 description 7
- 238000007796 conventional method Methods 0.000 description 6
- 201000001119 neuropathy Diseases 0.000 description 6
- 230000007823 neuropathy Effects 0.000 description 6
- -1 organic base Salts Chemical class 0.000 description 6
- 230000008929 regeneration Effects 0.000 description 6
- 238000011069 regeneration method Methods 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 102000007339 Nerve Growth Factor Receptors Human genes 0.000 description 5
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 235000013361 beverage Nutrition 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 235000013376 functional food Nutrition 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 210000002569 neuron Anatomy 0.000 description 5
- 210000000578 peripheral nerve Anatomy 0.000 description 5
- 208000033808 peripheral neuropathy Diseases 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 229930040373 Paraformaldehyde Natural products 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000007850 degeneration Effects 0.000 description 4
- 235000003599 food sweetener Nutrition 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 229920002866 paraformaldehyde Polymers 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 239000003765 sweetening agent Substances 0.000 description 4
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 208000028389 Nerve injury Diseases 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000032459 dedifferentiation Effects 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 239000003292 glue Substances 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 230000002132 lysosomal effect Effects 0.000 description 3
- 210000003712 lysosome Anatomy 0.000 description 3
- 230000001868 lysosomic effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000008764 nerve damage Effects 0.000 description 3
- 210000004498 neuroglial cell Anatomy 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 150000004728 pyruvic acid derivatives Chemical class 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 2
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 102000006386 Myelin Proteins Human genes 0.000 description 2
- 108010083674 Myelin Proteins Proteins 0.000 description 2
- 229920002230 Pectic acid Polymers 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010036105 Polyneuropathy Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 206010067722 Toxic neuropathy Diseases 0.000 description 2
- 231100000126 Toxic neuropathy Toxicity 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 206010073696 Wallerian degeneration Diseases 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000000783 alginic acid Chemical class 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000001130 astrocyte Anatomy 0.000 description 2
- 210000003050 axon Anatomy 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000007844 bleaching agent Substances 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- 230000003210 demyelinating effect Effects 0.000 description 2
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 230000028161 membrane depolarization Effects 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 230000029052 metamorphosis Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 210000005012 myelin Anatomy 0.000 description 2
- 230000009689 neuronal regeneration Effects 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 239000010318 polygalacturonic acid Substances 0.000 description 2
- 230000007824 polyneuropathy Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000019204 saccharin Nutrition 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 229940081974 saccharin Drugs 0.000 description 2
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 239000003656 tris buffered saline Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 230000008734 wallerian degeneration Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 208000003130 Alcoholic Neuropathy Diseases 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- 208000003808 Amyloid Neuropathies Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 208000006373 Bell palsy Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- ZKQDCIXGCQPQNV-UHFFFAOYSA-N Calcium hypochlorite Chemical compound [Ca+2].Cl[O-].Cl[O-] ZKQDCIXGCQPQNV-UHFFFAOYSA-N 0.000 description 1
- 206010061445 Cerebral cyst Diseases 0.000 description 1
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FEWJPZIEWOKRBE-LWMBPPNESA-L D-tartrate(2-) Chemical compound [O-]C(=O)[C@@H](O)[C@H](O)C([O-])=O FEWJPZIEWOKRBE-LWMBPPNESA-L 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 1
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010018341 Gliosis Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 229920002488 Hemicellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 102000002569 MAP Kinase Kinase 4 Human genes 0.000 description 1
- 108010068304 MAP Kinase Kinase 4 Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000010886 Peripheral nerve injury Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 239000004288 Sodium dehydroacetate Substances 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 208000020701 alcoholic polyneuropathy Diseases 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000021405 artificial diet Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 159000000009 barium salts Chemical class 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004791 biological behavior Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 208000003295 carpal tunnel syndrome Diseases 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 239000004459 forage Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 235000021182 hors d'oeuvre Nutrition 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 229960003350 isoniazid Drugs 0.000 description 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- BDRTVPCFKSUHCJ-UHFFFAOYSA-N molecular hydrogen;potassium Chemical compound [K].[H][H] BDRTVPCFKSUHCJ-UHFFFAOYSA-N 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 210000003007 myelin sheath Anatomy 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 230000007383 nerve stimulation Effects 0.000 description 1
- 230000003988 neural development Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 230000006576 neuronal survival Effects 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 208000027232 peripheral nervous system disease Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000007832 reinnervation Effects 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 235000019259 sodium dehydroacetate Nutrition 0.000 description 1
- 229940079839 sodium dehydroacetate Drugs 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- DSOWAKKSGYUMTF-GZOLSCHFSA-M sodium;(1e)-1-(6-methyl-2,4-dioxopyran-3-ylidene)ethanolate Chemical compound [Na+].C\C([O-])=C1/C(=O)OC(C)=CC1=O DSOWAKKSGYUMTF-GZOLSCHFSA-M 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- JBQYATWDVHIOAR-UHFFFAOYSA-N tellanylidenegermanium Chemical compound [Te]=[Ge] JBQYATWDVHIOAR-UHFFFAOYSA-N 0.000 description 1
- SDVHRXOTTYYKRY-UHFFFAOYSA-J tetrasodium;dioxido-oxo-phosphonato-$l^{5}-phosphane Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)P([O-])([O-])=O SDVHRXOTTYYKRY-UHFFFAOYSA-J 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to a pharmaceutical composition for the prevention or treatment of a peripheral nervous system degenerative disease comprising ethyl pyruvate or a pharmaceutically acceptable salt thereof as an active ingredient, A method for preventing or treating a neurodegenerative disease, a quasi-quasi-product composition for preventing or improving a peripheral nervous system degenerative disease, a food composition, and a feed composition.
Since ethylpyruvate suppresses the differentiation and proliferation of schwann cells, it can be very useful for the prevention and treatment of degenerative diseases of peripheral nervous system.
Description
The present invention relates to a pharmaceutical composition for the prevention or treatment of a peripheral nervous system degenerative disease comprising ethyl pyruvate or a pharmaceutically acceptable salt thereof as an active ingredient, A method for preventing or treating a neurodegenerative disease, a quasi-quasi-product composition for preventing or improving a peripheral nervous system degenerative disease, a food composition, and a feed composition.
Ethyl pyruvate (EP) is a derivative of pyruvate, which was developed to overcome the problem that pyruvate is very unstable in solution and low solubility, making it difficult to use as a therapeutic agent. The EP has been known to have the effect of improving the ischemia / reperfusion of the mesentery and the structural or functional damage of the intestinal mucosa in the rat (Carrie A. Sims et al., 2001, Crit. Care (Luis Ulloa et al., 2002, PNAS, 99, 19, 12351) have shown that administration of EP to rats with lethal sepsis prevents the lethal and systemic inflammation and increases the survival rate -12356) have been reported, but the effect on peripheral nerve injury has not been reported yet.
Peripheral neurodegeneration, on the other hand, has a different mechanism than central neurodegeneration. Cerebral cysts are formed in the injured area when the central nervous system is damaged, and neurons damaged by glial scars by astrocyte are not regenerated (Busch and Silver, 2007, Curr Opin Neurobiol, 17 , 120-127). On the other hand, in the peripheral nerve, damaged neurons are regenerated, which is called a Schwann cell, a type of glue cell, a glue cell that constitutes the central nervous system, astrocytes, oligodendrocyte, and microglia ), Thereby eliminating the myelin lumps that form during neuronal damage and affecting the regeneration of axons through cell proliferation. As described above, since the central nervous system degeneration and the peripheral nervous system degeneration have different mechanisms, degenerative diseases of the central nervous system and degenerative diseases of the peripheral nervous system are regarded as different diseases, and the target of treatment of degenerative peripheral nerve diseases is also a central neurodegenerative disease Unlike therapeutic targets, the development of therapeutic agents for the two diseases mentioned above requires a different approach to research.
When the peripheral nerve is damaged, a denaturation process called Wallerian degeneration occurs. The glial cells of the Schwann cell and the peripheral nervous system are demineralized into an immature state, and these cells are myelin-related (Jessen & Mirsky, 2008, Glia. 56: 1552-1565). Dehydration and proliferation of Schwann cells are essential for axon regeneration and reinnervation during neuronal regeneration. When exons are regenerated, schwann cells begin to proliferate and migrate, aligning the basal plate tubes that provide the substrate necessary for exon regrowth in the nerve (Asa Fex Svennigsen, 2013, Brain Sci. 3, 1182-1197). However, in the case of degenerative diseases of the peripheral nervous system such as Sarco maritus disease or dehydration diseases, Schwann cell depletion rather suppresses the regeneration process of the nerve by constantly promoting dehydration reduction (Krajewski KM, Brain. 2000 Jul, 123 ), 1516-27, Kissel JT, 2003 Jun, Semin Neurol, 23 (2), 169-80). Thus, inhibiting Schwann cell depletion can be usefully used to develop methods for treating peripheral nervous system degenerative diseases.
Under these circumstances, the present inventors have made extensive efforts to develop a therapeutic agent for degenerative diseases of peripheral nervous system. As a result, it has been found that ethylpyruvate, which is a stable derivative of pyruvate, inhibits dehisceration and proliferation of Schwann cells and inhibits various peripheral nervous system degenerative diseases The present invention has been completed.
An object of the present invention is to provide a pharmaceutical composition for the prevention or treatment of peripheral nervous system degenerative diseases comprising ethyl pyruvate or a pharmaceutically acceptable salt thereof as an active ingredient.
It is another object of the present invention to provide a method of preventing or treating a peripheral nervous system degenerative disease comprising administering the composition to a subject.
It is still another object of the present invention to provide a quasi-drug composition for preventing or ameliorating a peripheral nervous system degenerative disease comprising ethylpyruvate or a pharmaceutically acceptable salt thereof as an active ingredient.
It is still another object of the present invention to provide a food composition for preventing or ameliorating a peripheral nervous system degenerative disease comprising ethylpyruvate or a physiologically acceptable salt thereof as an active ingredient.
It is still another object of the present invention to provide a feed composition for preventing or ameliorating a peripheral nervous system degenerative disease comprising ethylpyruvate or a physiologically acceptable salt thereof as an active ingredient.
In order to accomplish the above object, one aspect of the present invention provides a pharmaceutical composition for the prevention or treatment of peripheral nervous system degenerative diseases comprising ethyl pyruvate or a pharmaceutically acceptable salt thereof as an active ingredient do.
Ethyl pyruvate inhibited the depolarization and proliferation of schwann cells inhibiting nerve regeneration in peripheral nervous system degenerative diseases. The composition of the present invention including ethylpyruvate is very useful for prevention and treatment of peripheral nervous system degenerative diseases Can be used.
The term "ethyl pyruvate" of the present invention means a derivative of pyruvate. It has not been known until now that the ethylpyruvate has a therapeutic effect on degenerative diseases of peripheral nervous system by suppressing Schwann cell depletion, Schwann cell proliferation, or a combination thereof, and it has been clarified for the first time by the present inventor.
In the present invention, ethylpyruvate may be synthesized by a known synthesis method, or may be isolated and purified from plants, or obtained commercially.
The "Schwann cell" is a type of glia cell that allows the peripheral nervous system fiber to survive. The Schwann cells perform various roles such as conduction of nerve stimulation, neural development and regeneration, nutrient supply to neurons, production of neuronal extracellular matrix, and are deeply involved in various biological behaviors of peripheral nerves.
The term " dedifferentiation "means a phenomenon in which a cell in a differentiated state changes into an undifferentiated state, loses its inherent characteristics, and regains its division ability. In the present invention, since differentiation of Schwann cells is induced by damage of the peripheral nerves, dedifferentiation of the Schwann cells can be used as a marker for nerve injury.
The term "proliferation" means that the number of cells increases through division. In the present invention, the proliferation of Schwann cells is induced by dedifferentiation of Schwann cells, and thus can be used as a marker for nerve injury.
The term "pharmaceutically acceptable" of the present invention means that it exhibits properties that are not toxic to the cells or humans exposed to the composition.
The term "pharmaceutically acceptable salt " of the present invention means salts in which the cation and the anion are pharmaceutically usable among the salts in which they are bound by electrostatic attraction. Usually, the salt is a salt with a metal salt, an organic base Salts with inorganic acids, salts with organic acids, salts with basic or acidic amino acids, and the like. For example, the metal salt may be an alkali metal salt (sodium salt, potassium salt, etc.), an alkaline earth metal salt (calcium salt, magnesium salt, barium salt, etc.), an aluminum salt and the like; Examples of salts with organic bases include salts with organic bases such as triethylamine, pyridine, picoline, 2,6-lutidine, ethanolamine, diethanolamine, triethanolamine, cyclohexylamine, dicyclohexylamine, N, And the like; The salt with inorganic acid may be a salt with hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid and the like; Salts with organic acids may be salts with formic acid, acetic acid, trifluoroacetic acid, phthalic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid and the like; Salts with basic amino acids may be salts with arginine, lysine, ornithine and the like; The salt with an acidic amino acid may be a salt with aspartic acid, glutamic acid and the like.
The compositions of the present invention include both pharmaceutically acceptable salts of ethyl pyruvate as well as possible solvates and hydrates thereof which may be prepared therefrom and may include all possible stereoisomers. The solvates, hydrates and stereoisomers of the ethylpyruvate can also be prepared using conventional methods.
The pharmaceutical composition of the present invention may further comprise a pharmaceutically acceptable carrier, excipient or diluent conventionally used in the production of a pharmaceutical composition, and the carrier may include a non-naturally occuring carrier .
Specifically, the pharmaceutical composition may be formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, oral preparations, suppositories and sterilized injection solutions according to a conventional method . In the present invention, the carrier, excipient and diluent which may be contained in the pharmaceutical composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, Calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. In the case of formulation, a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, or a surfactant is usually used. Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient such as starch, calcium carbonate, sucrose or lactose lactose, gelatin, and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid preparations for oral use may include various excipients such as wetting agents, sweetening agents, fragrances, preservatives, etc. in addition to water and liquid paraffin, which are simple diluents commonly used in suspension, liquid solutions, emulsions and syrups have. Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Examples of the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. Examples of suppository bases include witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin, and the like.
The term "peripheral nervous system degenerative disease " as used herein refers to diseases caused by necrosis or apoptosis of nerve cells that are constantly progressing in one or more parts of the peripheral nervous system, and includes metabolic, toxic, Heredity, and the like.
In the present invention, degenerative diseases of the peripheral nervous system include nutritional deficiency-related neuropathy including neurogenic beriberi, pelagra neuropathy and alcoholic neuropathy; Toxic neuropathy caused by drugs including isoniazid neuropathy, pyridoxine, and the like; Neuropathies associated with systemic metabolic diseases including amyloid neuropathy, diabetic neuropathy, diabetic muscular dystrophy and urinary toxic neuropathy; Guillain-Barre syndrome, Charcot-Marie-Tooth disease, chronic inflammatory dehydrative polyneuropathy, acute inflammatory dehydrative polyneuropathy, paratopoietic demyelinating peripheral neuropathy ( Paraproteinaemic Demyelinating Neuropathy), facial nerve paralysis, myasthenia gravis, and carpal tunnel syndrome; And other hereditary neuropathies, but the present invention is not limited thereto.
The term "prevention" of the present invention means any action that inhibits or delays the onset of peripheral nervous system degenerative diseases by the administration of the composition of the present invention.
The term "treatment" of the present invention means any suspicion of a peripheral nervous system degenerative disease by the administration of the composition of the present invention and any action that alleviates or alleviates symptoms of an onset.
In a specific embodiment of the present invention, ethyl pyruvate inhibits Schwann cell depletion by inhibiting the expression of p-ERK1 / 2, LAMP1 and p75 NGFR during Schwann cell depletion during Waller ' s degeneration (Figs. 1-3) And decreased the number of Ki67-positive cells, thereby suppressing Schwann cell proliferation (Fig. 4). This suggests that ethylpyruvate can be effectively used for the treatment or prevention of peripheral nervous system degenerative diseases.
Another aspect of the present invention relates to a pharmaceutical composition for preventing or treating a peripheral nervous system degenerative disease comprising ethylpyruvate or a pharmaceutically acceptable salt thereof as an active ingredient, Thereby preventing or treating the disease.
Such ethylpyruvate, pharmaceutically acceptable salt, peripheral nervous system degenerative disease, prevention and treatment are as described above.
The term "administering" of the present invention means introducing a given substance into a subject in an appropriate manner.
The term "individual" of the present invention means all animals including mice, mice, livestock and the like, including humans who have developed or are capable of developing peripheral nervous system degenerative diseases. But are not limited to, mammals including humans. In addition, in the present invention, an individual may be excluded from human, but is not limited thereto.
The term "pharmaceutically effective amount" of the present invention means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment and not causing side effects. The effective dose level is determined by the sex, age And other medical fields, including drugs used in combination or concurrently, with respect to body weight, health status, type of disease, severity, activity of the drug, sensitivity to the drug, method of administration, administration time, route of administration, Can be readily determined by those skilled in the art according to well known factors.
Specifically, the composition of the present invention may be administered at a dose of 0.0001 to 100 mg / kg body weight per day, more specifically 0.001 to 100 mg / kg body weight, based on the solid content. The administration may be such that the recommended dose is administered once a day or divided into several doses.
In addition, the composition of the present invention can be administered specifically so that ethylpyruvate or a pharmaceutically acceptable salt thereof can be administered to an individual at a concentration of 0.01 mM to 1000 mM, more specifically, 0.1 mM to 100 mM. It is not limited.
In the method for the prevention or treatment of peripheral nervous system degenerative diseases of the present invention, the administration route and method of administering the composition are not particularly limited, and any administration can be used as long as the composition containing the composition can reach the desired site Route and mode of administration. Specifically, the composition may be administered orally or parenterally through various routes. Non-limiting examples of routes of administration include oral, rectal, topical, intravenous, intraperitoneal, intramuscular, intraarterial, transdermal, Intramuscularly or through inhalation or the like.
Another aspect of the present invention provides a quasi-drug composition for preventing or ameliorating a peripheral nervous system degenerative disease comprising ethylpyruvate or a pharmaceutically acceptable salt thereof as an active ingredient.
Such ethylpyruvate, pharmaceutically acceptable salts, peripheral nervous system degenerative diseases and prevention are as described above.
The term "improvement" of the present invention means any action in which the degenerative disease of the peripheral nervous system is alleviated or modified by administration of the composition of the present invention.
The term "quasi-drug" of the present invention means a fiber, a rubber product or the like used for the purpose of treating, alleviating, treating or preventing a disease of a human or an animal, A product which is similar to a non-machine and similar product, a product used for sterilization, insecticide and similar uses for the prevention of infection, which is used for diagnosis, treatment, alleviation, treatment or prevention of a disease of human or animal Means an article other than an apparatus, a machine or an apparatus, and an article other than an apparatus, a machine or an apparatus used for the purpose of giving a pharmacological effect to the structure and function of a person or an animal, But is not limited thereto.
When ethylpyruvate or a pharmaceutically acceptable salt thereof is added to a quasi-drug composition for the purpose of preventing or ameliorating a peripheral nervous system degenerative disease, the ethylpyruvate or a pharmaceutically acceptable salt thereof may be added intact or other quasi-drugs And may be suitably used according to a conventional method. The amount of the active ingredient to be mixed can be appropriately determined depending on the purpose of use.
The external preparation for skin may be manufactured and used in the form of, for example, an ointment, a lotion, a spray, a patch, a cream, a powder, a suspension, a gel or a gel.
The quasi-drug composition of the present invention may be contained in various weight percentages as long as it can exhibit a preventive or ameliorative effect of a peripheral nervous system degenerative disease. Specifically, ethyl pyruvate or a pharmaceutically acceptable salt thereof may be contained in an amount of 0.01 - 100% by weight, more specifically 1 to 80% by weight.
Another aspect of the present invention provides a food composition for preventing or ameliorating a peripheral nervous system degenerative disease comprising ethylpyruvate or a physiologically acceptable salt thereof as an active ingredient.
The ethyl pyruvate, peripheral nervous system degenerative diseases, prevention and improvement are as described above.
The term "physiologically acceptable salt" of the present invention means a compound which is physiologically acceptable and which, when administered to an organism, does not normally cause an allergic reaction such as gastrointestinal disorder, dizziness, Quot; and " the "
The term "improvement" of the present invention means any action in which the degenerative disease of the peripheral nervous system is alleviated or modified by administration of the composition of the present invention.
The term "food" of the present invention is intended to encompass all kinds of foods, such as meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, ice cream, Vitamin complex, health functional food, and health food, all of which include foods in a conventional sense.
The term "functional food" as used herein is the same term as "food for special health use" (FoSHU). In addition to nutritional supplementation, functional foods are processed so as to efficiently show the biological control function, It means food. Here, the term "function (surname)" means that the structure and function of the human body have a beneficial effect for health use such as controlling nutrients or physiological action. The food of the present invention can be prepared by a method commonly used in the art and can be prepared by adding raw materials and ingredients which are conventionally added in the art. In addition, the formulations of the food can also be produced without restrictions as long as they are formulations recognized as food. The composition for food of the present invention can be manufactured in various forms, and unlike general pharmaceuticals, it has the advantage that there is no side effect that may occur when a drug is used for a long period of time, and is excellent in portability, Can be ingested as an adjuvant to enhance the effect of preventing or improving peripheral nervous system degenerative diseases.
The health food refers to a food having an active health promotion or promotion effect compared with a general food, and a health supplement food refers to a food for health assistance. In some cases, the terms health functional foods, health foods, and health supplements are used.
Specifically, the health functional food is a food prepared by adding ethylpyruvate or a physiologically acceptable salt thereof to a food material such as beverage, tea, spice, gum, confectionery, or the like, or by encapsulation, powdering, , It means to bring about a certain effect on health when consumed, but unlike general medicine, there is an advantage that there is no side effect that can occur when a drug is taken for a long time by using food as a raw material.
Since the food composition of the present invention can be routinely ingested, it can be expected that the effect of preventing or improving a peripheral degenerative disease of the peripheral nervous system is expected to be very useful.
The composition may further include a physiologically acceptable carrier. The carrier is not particularly limited and any carrier conventionally used in the art can be used.
In addition, the composition may contain additional ingredients which are commonly used in food compositions and which can improve odor, taste, vision and the like. For example, vitamins A, C, D, E, B1, B2, B6, B12, niacin, biotin, folate, panthotenic acid and the like. In addition, it may include minerals such as zinc (Zn), iron (Fe), calcium (Ca), chromium (Cr), magnesium (Mg), manganese (Mn), copper (Cu) It may also include amino acids such as lysine, tryptophan, cysteine, valine, and the like.
In addition, the composition can be used in combination with a preservative (potassium sorbate, sodium benzoate, salicylic acid, sodium dehydroacetate), a disinfectant (such as bleaching powder and highly bleached white powder, sodium hypochlorite), an antioxidant (butylhydroxy anisole (BHA) (Sodium hypophosphate), bleach (sodium sulfite), seasoning (sodium MSG glutamate, etc.), sweeteners (hemicellulose, cyclamate, saccharin, A food additive such as a flavor (vanillin, lactones), a swelling agent (alum, D-tartrate, potassium hydrogen), an emulsifier, a thickening agent (glue), a covering agent, a gum base agent, a foam inhibitor, and food additives. The additives may be selected and used in appropriate amounts depending on the type of food.
The ethylpyruvate or a physiologically acceptable salt thereof may be added intact or used together with other food or food ingredients, and may be suitably used according to a conventional method. The amount of the active ingredient to be mixed can be suitably determined according to its intended use (prevention, health or therapeutic treatment). Generally, the food composition of the present invention may be added in an amount of not more than 50 parts by weight, specifically not more than 20 parts by weight, based on the food or beverage, when the food or drink is prepared. However, in case of long-term ingestion for health and hygiene purposes, the active ingredient may be contained in an amount not exceeding the above range and there is no problem in terms of safety.
As an example of the food composition of the present invention, it can be used as a health beverage composition. In this case, various flavors or natural carbohydrates can be added as an additional ingredient such as ordinary beverages. The above-mentioned natural carbohydrates include monosaccharides such as glucose and fructose; Disaccharides such as maltose, sucrose; Polysaccharides such as dextrin, cyclodextrin; Xylitol, sorbitol, erythritol, and the like. Sweeteners include natural sweeteners such as tau Martin and stevia extract; Synthetic sweetening agents such as saccharin and aspartame, and the like can be used. The ratio of the natural carbohydrate may be generally about 0.01 to 0.04 g, specifically about 0.02 to 0.03 g per 100 mL of the composition of the present invention.
In addition to the above, the health beverage composition may contain various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid, salts of pectic acid, alginic acid, salts of alginic acid, organic acid, protective colloid thickener, pH adjuster, stabilizer, Alcohols or carbonating agents, and the like. It may also contain flesh for the production of natural fruit juices, fruit juice drinks, or vegetable drinks. These components may be used independently or in combination. The proportion of such additives is not critical, but is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.
The food composition of the present invention may be contained in various weight percentages as long as it can exhibit a preventive or ameliorative effect of peripheral nervous system degenerative diseases. Specifically, the ethyl pyruvate may be contained in an amount of 0.00001 to 100% by weight or 0.01 to 100% by weight, 80% by weight.
Another aspect of the present invention provides a feed composition for preventing or ameliorating a peripheral nervous system degenerative disease comprising ethylpyruvate or a physiologically acceptable salt thereof as an active ingredient.
The ethyl pyruvate, physiologically acceptable salt, peripheral nervous system degenerative disease, prevention and improvement are as described above.
The term "feed" of the present invention includes any of natural or artificial diets, hors d'oeuvres, etc., or ingredients of the above formula for feeding, ingesting, digesting, or containing the above-mentioned ethyl pyruvate as an active ingredient The feeds can be made into various types of feeds known in the art, and may specifically include concentrated feeds, forage and / or special feeds.
The ethylpyruvate or a physiologically acceptable salt thereof contained in the feed composition of the present invention may vary depending on the purpose of use and the conditions of use of the feed. For example, the ethylpyruvate or the physiologically acceptable salt thereof may be 0.01 to 100% , More specifically from 1 to 80% by weight.
Ethyl pyruvate inhibits the depolarization and proliferation of Schwann cells that inhibit neuronal regeneration in peripheral nervous system degenerative diseases, and thus can be very useful for the prevention and treatment of peripheral nervous system degenerative diseases.
Fig. 1 shows the effect of EP (10 mM) inhibiting p-ERK1 / 2 expression (Con: uninjured control nerve, 3DIV: injured experimental nerve not treated with EP, 3DIV / EP: EP One injured experimental nerve).
1 (a) is an image showing a cross section of a sciatic nerve section subjected to double immunostaining for p-ERK1 / 2 (red) and S100 (green, Schwann cell marker). Under conditions in which EP (1 or 10 mM) was present or absent, sciatic nerve slices were incubated for three days (three days in vitro; 3DIV). Scale bar = 50 占 퐉.
FIG. 1 b is a graph showing the percentage of p-ERK1 / 2-positive cells among 200 S100-positive cells (n = 4, * P <0.001).
Fig. 1 (c) shows the result of Western blot analysis of the protein lysate (10 占 퐂) obtained from the sciatic nerve treated with 10 mM EP.
Figure 1 (d) is the result of quantifying the relative intensities of p-ERK1 and p-ERK2 expression by Western blotting (n = 4, * P <0.001).
Fig. 2 shows the lysosomal activity inhibited by EP (10 mM) (Con: uninjured control nerve, 3DIV: injured experimental nerve not treated with EP, injured experimental nerve treated with 3DIV / EP: EP) .
FIG. 2 (a) is an image showing the result of performing double immunostaining using scissored sciatic nerve fibers using LAMP1 (red, a lysosomal follicle marker) and S100 (green). Scale bar = 100 占 퐉.
2 (b) is a graph showing the result of quantifying the fluorescence intensity of LAMP1 immunoreactivity in the cut nerve fiber sample (n = 3, * P < 0.001).
2C is an image showing the result of Western blotting of LAMP1. β-actin was used as a loading control.
2 (d) is a graph showing the result of quantifying the concentration of LAMP1 expression (n = 3, * P < 0.001).
Figure 3 shows the expression of p75NGFR regulated by EP (10 mM) (Con: uninjured control nerve, 3DIV: injured experimental nerve not treated with EP, injured experimental nerve treated with 3DIV / EP: EP) .
Fig. 3 (a) is an image showing the results of immunohistochemical staining of scissored sciatic nerve with p75 NGFR (red) and S100 (green). Scale bar = 100 占 퐉.
Fig. 3 (b) is a graph showing the fluorescence intensity of p75 NGFR expression (n = 3, * P < 0.001).
FIG. 3C is a Western blot image showing that the expression of p75NGFR is decreased in the sciatic nerve section treated with EP. β-actin was used as a loading control.
FIG. 3 (d) is a graph showing the result of quantifying the Western blot band (n = 4, * P <0.001).
FIG. 4 shows the effect of EP (10 mM) inhibiting Schwann cell proliferation during Waller denaturation (Con: uninjured control nerve, 3DIV: injured experimental nerve not treated with EP, 3DIV / EP: EP Treated injured experimental nerve).
4 (a) is an image showing a section of a mouse sciatic nerve section double-stained with Ki67 (red, cell growth marker) and S100. Scale bar = 50 占 퐉.
FIG. 4B is a graph showing the average percentage of Ki67-positive cells among 200 DAPI-positive cells shown in FIG. 4A (n = 4, * P <0.001).
Hereinafter, the constitution and effects of the present invention will be described in more detail through examples. These embodiments are only for illustrating the present invention, and the scope of the present invention is not limited by these embodiments.
Experimental Example 1. Experimental animals
Five-week-old C57BL / 6 male mice (Samtako, Osan, Korea) were used for the experiments. The mice were housed in an ad libitum environment with a temperature of 23 1 C, a humidity of 50% and a light / dark cycle of 12 hours, and food and water were available. All animals were used in accordance with the Animal Experimental Guidelines published in the Medical Association under the approval of the Kyung Hee University School Committee on Animal Research (KHUASP (SE) -13-027). All courses used minimal animals and the animals were designed to suffer the least pain.
Experimental Example 2. Materials
The primary antibody used for immunostaining or Western blotting was purchased and used. Specifically, p75NGFR (p75 nerve growth factor receptor) and LAMP1 were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA), phosphorylated 44/42 MAPK (p-ERK1 / 2) and Ki67 were Cell Signaling MA, USA) and Abcam (Cambridge, UK). Alexa Fluor 488-conjugated and 594-conjugated secondary antibodies were purchased from Life Technologies (Grand Island, NY, USA). Other antibodies and reagents were purchased from Sigma-Aldrich (St. Louis, MO, USA).
Experimental Example 3. Slice culture ( Explant culture)
Sciatic nerve explants were cultured according to the conventional method (Park et al., 2015, J Neurochem., 132: 230-242). Specifically, after separating the sciatic nerve from the mouse, the connective tissue surrounding the nerve was separated using a stereomicroscope, and the sciatic nerve was cut into three or four sections 3-4 mm long. A sciatic nerve fragment fixed with 4% paraformaldehyde (PFA) was used as a control immediately after separation from the mouse. The sciatic nerve slices used as Wallerian degeneration models were treated with 100 units / mL penicillin, 100 μg / ml streptomycin, 10% heat-inactivated fetal bovine serum , And 2 mM L-glutamine (Dulbecco's modified Eagle's medium, Thermo, Waltham, Mass., USA) at 5% CO 2 and 37 ° C. In all experiments, sciatic nerve slices were incubated for 3 days and then fixed with 4% PFA for 6-12 hours for immunostaining or homogenized to obtain protein extracts.
Experimental Example 4. Western blot (Western blot) analysis
Western blot analysis was performed according to the conventional method (Lee et al. 2007, J Neurochem. 102: 686-698). Specifically, the protein (10 μg) obtained from the cultured sciatic nerve slices was separated by using 10% SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis), and the separated proteins were electrophoretically transferred to a nitrocellulose membrane Amersham Bioscience, Piscataway, NJ, USA). A solution prepared by mixing TBS (Tris-buffered saline) with 0.05% Tween-20 (TBST) in an additional 5% nonfat milk was treated at 4 ° C for blocking all day The membrane was then allowed to hybridize with the appropriate primary antibody at 25 < 0 > C for 1 hour. The proteins migrated to the membrane were detected by Ponceau S staining. For quantitative analysis, X-ray film was scanned using HP scanner and analyzed using LAS image analysis system (Fujifilm, Tokyo, Japan).
Experimental Example 5. Immunostaining ( Immunostaining )
Sciatic explant slides were fixed with 4% PFA for 20 minutes, washed three times with PBS (phosphate-buffered saline) for 10 minutes, and then resuspended in 0.3% Triton X-100 (PBST) And blocked with PBS containing bovine serum albumin for 1 hour. The slides were then immersed in a blocking solution at 4 ° C containing the corresponding primary antibody overnight. The slide was washed three times and immersed in PBST containing Alexa 488-conjugated or 594-conjugated secondary antibody for 2 hours at room temperature. The coverslips were attached to the slides using Gelmount (Biomeda, Foster City, CA, USA), and then transferred to a slide using a laser confocal microscope (LSM710, Carl Zeiss, Oberkochen , Germany). For the morphological analysis of LAMP1 immunofluorescence, software with LSM 710 microscope was used. The intensity of fluorescence was calculated in the area of 300 x 300 탆 2 arbitrarily selected from three mice selected from each sample. The relative number of pixels showing each intensity unit was investigated to determine the relative intensity (Lee et al. 2009, J Neurochem. 108: 776-786).
Experimental Example 6. Statistical analysis
All experiments were performed at least three times, and each value was expressed as mean ± SEM (Standard Error of the Mean). Statistical significance between the groups was assessed using the one-way analysis of variance. All analyzes were performed using SPSS 21.0 software (IBM, USA).
The results confirmed in the above Experimental Examples are summarized in the following Examples.
Example One. EP's Schwann cells Depletion Check for inhibition
Example 1-1. EP's p- ERK1 / 2 expression inhibition confirmation
Depletion of Schwann cells following injury to peripheral nerves is associated with activation of MAP kinases, including JNK, ERK, and p38 MAP kinases (Yang et al., 2012, J Neurosci. 32: 7158-7168 ), After nerve injury, ERK1 / 2 is phosphorylated at the distal stump (p-ERK1 / 2). To investigate whether EP inhibited Schwann cell depletion during Walla's degeneration, sciatic nerve slices were treated with EP (1 or 10 mM) for three days (three days in vitro; 3DIV) and immunostained The effect of EP on p-ERK1 / 2 was investigated.
As a result, the level of p-ERK1 / 2 was significantly increased in injured but non-EP treated nerves (3DIV) compared to the uninjured nerve (control; con) It is confirmed that the marker is located at the same position as S100. On the other hand, the sciatic nerve slice treated with 10 mM EP showed similar level of expression of p-ERK1 / 2 to that of the control. In the case of 1 mM of EP, the expression of p-ERK1 / (Fig. 1 (a) and (b)). Therefore, it was judged that 10 mM of EP was suitable for suppressing Schwann cell depletion.
In addition, the effect of EP on the expression of p-ERK1 / 2 was quantitatively analyzed by Western blot analysis. The sciatic nerve slices treated with 10 mM of EP showed less expression of p-ERK1 / 2 than the control or 3DIV. Thus, it was confirmed that EP inhibited the induction of p-ERK1 / 2 (c and d in Fig. 1).
These results indicate that EP can inhibit Schwann cell depletion by inhibiting p-ERK1 / 2 expression during Schwann cell depletion during Waller denaturation.
Example 1-2. EP's LAMP1 Confirmation of expression inhibition
In dedifferentiated schwann cells, protein degradation by lysosomes and proteosomes is activated to remove myelin sheath debris and expression of LAMP1, a marker of the vesicles of the lysosomes, (Shin et al., 2013, Biochem Biophys Res Commun. 430: 852-857). Thus, immunostaining for LAMP1 and S100 was performed to confirm that EP inhibited lysosomal activity during Waller denaturation.
As a result, it was confirmed that the staining intensity of LAMP1 was lower than that of the 3DIV not treated with EP (3DIV / EP) for 3 days, and it was confirmed that the immunoreactivity to LAMP1 was decreased 2, a and b).
In addition, Western blot analysis was conducted to quantitatively analyze the effect of EP on the expression of LAMP1. In addition, the relative density of Western blot was quantitatively analyzed by using Image J software to quantitatively assess the expression of LAMP1 by EP treatment (Lee et al., 2014, J Exp Med., 211: 1551-1570). The sciatic nerve slices treated with 10 mM of EP showed significantly lower expression of LAMP1 than the control or 3DIV. As a result, it was confirmed that EP suppressed the expression of LAMP1 (Fig. 2 (c) and (d)).
From the above results, it was confirmed that EP can inhibit Schwann cell depletion by significantly inhibiting protein degradation by lysosome during Schwann cell depletion during Waller denaturation.
Example 1-3. EP's p75NGFR Confirmation of expression inhibition
Depleted schwann cells during Waller metamorphosis induce the expression of neurotrophic factors associated with neuronal survival and axonal regeneration (Chen et al. 2007, J Neurochem. 85: 443-453) . P75NGFR, a low affinity NGFR, is expressed at high levels in dedifferentiated Schwann cells during Waller denaturation (Shin et al., 2013, Biochem Biophys Res Commun. 430: 852-857). Therefore, in order to investigate whether EP suppresses the expression of p75NGFR and suppresses Schwann cell depletion, the sciatic nerve slice was immunostained with p75NGFR antibody.
As a result, it was confirmed that the p75NGFR staining intensity was significantly lower than that of the non-EP treated 3DIV when treated with EP for 3 days (3DIV / EP), thereby confirming that p75NGFR expression was inhibited Of a and b).
In addition, Western blot analysis was performed to quantitatively analyze the effects of EP on the expression of p75NGFR. The sciatic nerve slices treated with 10 mM of EP showed significantly less expression of p75NGFR than the control or 3DIV. This confirmed that EP inhibited the expression of p75NGFR (c and d in Fig. 3).
From these results, it was confirmed that EP inhibits Schwann cell depletion by inhibiting p75NGFR expression during Schwann cell depletion during Waller denaturation.
Example 2. EP's Verification of Schwann cell proliferation inhibition
Since Schwann cell proliferation is a distinctive feature of Waller metamorphosis, the effect of EP on Waller metamorphism was confirmed by immunostaining with Ki67, a cell proliferation marker.
As a result, it was confirmed that Ki67 signal was increased in the section of 3DIV neurons not treated with EP, and that Ki67 was located in S100-positive and DAPI-positive cells (FIGS. 4A and 4B) . However, by confirming that the number of Ki67-positive cells in the sciatic nerve section treated with 10 mM of EP was lower than that of 3DIV, EP confirmed that the proliferation of schwann cells during Waler's denaturation of sciatic nerve slices was suppressed.
From the above description, it will be understood by those skilled in the art that the present invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. In this regard, it should be understood that the above-described embodiments are to be considered in all respects as illustrative and not restrictive. The scope of the present invention should be construed as being included in the scope of the present invention without departing from the scope of the present invention as defined by the appended claims.
Claims (8)
Wherein said peripheral nervous system dehydration disease is Guillain-Barre syndrome, or Charcot-Marie-Tooth disease type 2.
Wherein said peripheral nervous system dehydration disease is Guillain-Barre syndrome, or Charcot-Marie-Tooth disease type 2.
Wherein said peripheral nervous system dehydration disease is Guillain-Barre syndrome, or Charcot-Marie-Tooth disease type 2.
Wherein said peripheral nervous system dehydration disease is Guillain-Barre syndrome, or Charcot-Marie-Tooth disease type 2.
Wherein said peripheral nervous system dehydration disease is Guillain-Barre syndrome, or Charcot-Marie-Tooth disease type 2.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020150147394A KR101840092B1 (en) | 2015-10-22 | 2015-10-22 | A pharmaceutical composition for preventing or treating peripheral neurodegenerative diseases comprising ethyl pyruvate |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020150147394A KR101840092B1 (en) | 2015-10-22 | 2015-10-22 | A pharmaceutical composition for preventing or treating peripheral neurodegenerative diseases comprising ethyl pyruvate |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20170047458A KR20170047458A (en) | 2017-05-08 |
KR101840092B1 true KR101840092B1 (en) | 2018-03-20 |
Family
ID=60163962
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020150147394A KR101840092B1 (en) | 2015-10-22 | 2015-10-22 | A pharmaceutical composition for preventing or treating peripheral neurodegenerative diseases comprising ethyl pyruvate |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101840092B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20190087571A (en) * | 2016-12-14 | 2019-07-24 | 에스케이바이오팜 주식회사 | Use of carbamate compounds for the prevention, alleviation or treatment of dehydrative diseases |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109588559A (en) * | 2019-01-28 | 2019-04-09 | 湖北浩华生物技术有限公司 | The application of ethyl pyruvate and feed |
-
2015
- 2015-10-22 KR KR1020150147394A patent/KR101840092B1/en active IP Right Grant
Non-Patent Citations (2)
Title |
---|
Neuroprotective effect of ethyl pyruvate in vincristine and cisplatin induced neuropathic pain, International Journal of Nutrition, Pharmacology, Neurological Diseases, 4(4), 214-225(2014.10-11)* |
Oxidative Stress and Proinflammatory Cytokines Contribute to Demyelination and Axonal Damage in a Cerebellar Culture Model of Neuroinflammation, PLoS One., 8(2), e54722(2013.) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20190087571A (en) * | 2016-12-14 | 2019-07-24 | 에스케이바이오팜 주식회사 | Use of carbamate compounds for the prevention, alleviation or treatment of dehydrative diseases |
KR102635936B1 (en) | 2016-12-14 | 2024-02-13 | 에스케이바이오팜 주식회사 | Use of carbamate compounds for preventing, alleviating or treating demyelinating diseases |
Also Published As
Publication number | Publication date |
---|---|
KR20170047458A (en) | 2017-05-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101308232B1 (en) | Composition for preventing and treating neurological disorder comprising osmotin | |
US11459311B2 (en) | Pharmaceutical composition containing indirubin derivative as active ingredient | |
KR101840092B1 (en) | A pharmaceutical composition for preventing or treating peripheral neurodegenerative diseases comprising ethyl pyruvate | |
KR102524364B1 (en) | Composition for preventing or treating periodontitis comprising cannabidiol and taurine | |
KR101749967B1 (en) | A pharmaceutical composition comprising extract from germinated gemmule of bean for preventing or treating obesity | |
KR102081984B1 (en) | A pharmaceutical composition comprising extract from wheat sprowt for preventing or treating osteoporosis | |
JP6000206B2 (en) | Antiallergic oral composition | |
KR20190058346A (en) | Composition comprising chp (cyclo-his pro) for preventing, improving or treating of bone loss related disease | |
KR20200043711A (en) | Composition for improving muscular quality comprising Eisenia bicyclis extract or its fraction | |
KR102421601B1 (en) | Composition for Preventing or Treating Neurodegenerative Diseases | |
KR102101662B1 (en) | Antidiabetic and antioxidant compositions comprising Flavonoid 8-O-glucuronide compounds | |
KR101448155B1 (en) | Composition containing 3-methyladenine for inhibiting or treating neuropathic pain | |
JP7106340B2 (en) | Blood-brain barrier protectant | |
KR20150086429A (en) | Composition for preventing or treating neurological disorder induced by excitotoxicity or synaptic dysfunction, and method for preventing or treating neurological disorder using the same | |
KR101656175B1 (en) | Pharmaceutical composition for preventing or treating peripheral neurodegenerative diseases comprising an inhibitor of Hydrogen sulfide production | |
KR102294523B1 (en) | Composition for protecting neuronal cells comprising ginsenoside Rb2 | |
KR102588274B1 (en) | Pharmaceutical composition for preventing or treating epilepsy or seizure-related diseases comprising D-limonene as an active ingredient | |
JP6113325B2 (en) | Antiallergic oral composition | |
US20230293482A1 (en) | Central nervous system potentiating composition | |
JP7333626B2 (en) | Composition for preventing and treating Alzheimer's dementia, composition for reducing amyloid β oligomer neurotoxicity | |
KR101392177B1 (en) | Composition comprising 3,3'-diindolylmethane for preventing and treating hyperosmia | |
WO2020213616A1 (en) | A composition for prevention and/or treatment for alzheimer's disease and/or alzheimer dementia, and a composition for reducing amyloid-beta oligomer neurotoxicity | |
EP4248957A1 (en) | Method for treating non-alcoholic steatohepatitis through co-administration of curcumin derivative and tgf-? receptor inhibitor | |
KR102131350B1 (en) | Composition for preventing or treating diabetes comprising (3S,5R,6R,7E,9R)-3,5,6,9-tetrahydroxy-7-megastigmene | |
KR101340675B1 (en) | Pharmaceutical composition comprising tangeretin for preventing or treating cardiovascular diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
AMND | Amendment | ||
X701 | Decision to grant (after re-examination) | ||
GRNT | Written decision to grant |